Ignite Creation Date:
2024-05-06 @ 2:29 AM
Last Modification Date:
2024-10-26 @ 11:19 AM
Study NCT ID:
NCT02053636
Status:
COMPLETED
Last Update Posted:
2020-01-03
First Post:
2014-01-24
Brief Title:
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Sponsor:
Institut de Recherches Internationales Servier
Organization:
Servier
Study Overview
Official Title:
An Open 3-cohort Phase II Trial Testing Oral Administration of Lucitanib in Patients With FGFR1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
Status:
COMPLETED
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
FINESSE
Brief Summary:
The aim of the study is to evaluate the objective response rate ORR of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified FGFR1-non amplified with 11q amplification or FGFR1-non amplified without 11q amplification
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BIG 2-13 | OTHER | BIG | None |
| 2013-000288-10 | EUDRACT_NUMBER | None | None |